Epigenetic basis of cancer drug resistance

References

[1] Peters GJ.Cancer drug resistance: a new perspective..Cancer Drug Resist2018;1:1-5

[2] Ahmad A.Editorial: cancer epigenetics..Curr Cancer Drug Targets2018;18:3-4

[3] Ahmad A.Cancer epigenetics: clinical perspectives..Curr Cancer Drug Targets2019;19:513-4

[4] Ahmad A,Ginnebaugh KR,Bao B.Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs..J Hematol Oncol2013;6:77 PMCID:PMC3852827

[5] Lu Y,Oeck S.Hypoxia promotes resistance to EGFR inhibition in NSCLC Cells via the histone demethylases, LSD1 and PLU-1..Mol Cancer Res2018;16:1458-69 PMCID:PMC6170700

[6] Yue J,Wang C,Zhao Q.Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3..Oncogene2018;37:4300-12 PMCID:PMC6072709

[7] White JC,Crea F.The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors..Cancer Drug Resist2019;2:326-34

[8] Moufarrij S,Arthofer E,Srivastava A.Epigenetic therapy for ovarian cancer: promise and progress..Clin Epigenetics2019;11:7 PMCID:PMC6334391

[9] Schwarzenbach H.Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients..Cancer Drug Resist2019;2:271-96

[10] Ahmad A.Epigenetics in personalized management of lung cancer..Adv Exp Med Biol2016;890:111-22

[11] Malone ER,Sabatini PJB,Siu LL.Molecular profiling for precision cancer therapies..Genome Med2020;12:8 PMCID:PMC6961404

[12] Goutsouliak K,Sethunath V,Osborne CK.Towards personalized treatment for early stage HER2-positive breast cancer..Nat Rev Clin Oncol2019;Epub ahead of print. doi: 10.1038/s41571-019-0299-9

[13] Ponnusamy L,Chang YW.Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer..Cancer Drug Resist2019;2:297-312

[14] Seno A,Aizawa K,Masuda J.Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation..Cancer Drug Resist2019;2:335-50

[15] Janczar S,Pastorczak A,Paige AJW.The role of histone protein modifications and mutations in histone modifiers in pediatric B-cell progenitor acute lymphoblastic leukemia..Cancers (Basel)2017;9: PMCID:PMC5295773

[16] Meyer LK.The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities..Cancer Drug Resist2019;2:313-25

[17] Jia ZH,Zhang H.Overcome cancer drug resistance by targeting epigenetic modifications of centrosome..Cancer Drug Resist2019;2:210-24

[18] Galon J.Tumor immunology and tumor evolution: intertwined histories..Immunity2020;52:55-81

[19] Peixoto P,Boyer-Guittaut M.Epigenetics, a key player of immunotherapy resistance..Cancer Drug Resist2018;1:219-29

[20] Morales S,Navarro A.Epigenetic regulation mechanisms of microRNA expression..Biomol Concepts2017;8:203-12

[21] Ahmad A,Bao B,Sarkar FH.Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals..Mol Nutr Food Res2014;58:79-86 PMCID:PMC3997058

[22] Ediriweera MK.Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer..Pharmacol Ther2019;206:107437

[23] Biersack B.Alkylating anticancer agents and their relations to microRNAs..Cancer Drug Resist2019;2:1-17